Industry executives predict the next 'blue oceans' in pharma

Where life science leaders see breakthroughs happening in the industry.

By Taren Grom • Feb. 4, 2022

Komodo Health's partnership with Chan Zuckerberg Initiative gives 50 rare disease patient organizations access to next-generation analytics

With 330 million patient healthcare encounters in its database, Komodo assists advocacy organizations in gaining insights on specific patient populations.

By Robin Robinson • Feb. 3, 2022

Explore the Trendline➔

Emerging biotech

After years of financial turmoil, the biotech market is turning the page. Strong fundamentals, including solid clinical data, are key for biotechs hoping to capitalize on the improving conditions.  

By PharmaVoice staff

Woman of the Week: Syneos Health's president of commercial solutions, Michelle Keefe

How Michelle Keefe, president, commercial solutions at Syneos Health, steered her team into a rapid pivot during the pandemic.

By Taren Grom • Feb. 2, 2022

Talent acquisition stays top of mind for pharma execs

From creating flexible work environments to looking outside the industry for new talent, pharma execs are shifting strategies to keep their teams afloat.

By Taren Grom • Feb. 1, 2022

For the CEO of Travere, running a rare disease company is personal

To kick off Rare Disease month, we interview the CEO of Travere Therapeutics

By Kim Ribbink • Feb. 1, 2022

Biopharma's R&D leaders on how technology can accelerate drug development

How emerging digital tools are providing enhanced clinical insights and improved trial results.

By Taren Grom • Jan. 27, 2022

Sanofi's chief scientist on why 'this is the moment' for AI in Big Pharma

How a $5.2 billion AI investment is enabling the French pharma to accelerate drug development. 

By Meagan Parrish • Jan. 27, 2022

With its wealth of patient data, Walgreens is looking to disrupt the clinical trial space

How the mega-pharmacy’s clinical trials officer is looking to capitalize on its deep well of patient data to create an interconnected healthcare system of the future.

By Taren Grom • Jan. 26, 2022

Woman of the Week: Janssen's Dr. Sylvie Laquerre

Why following the science is crucial when bringing new compounds to market.  

By Taren Grom • Jan. 26, 2022

How AI is helping pharma solve some of its COVID problems

With the pressure still on pharma to innovate quickly and go digital, the use-cases for AI are increasing in stride.

By Meagan Parrish • Jan. 25, 2022

One man's quest to boost the patient's role in clinical trials

How a personal diagnosis inspired Craig Lipset to transform patient involvement in medical research.

By Robin Robinson • Jan. 24, 2022

Leaders predict improving patient engagement will lead to growth opportunities

Why patient engagement is key to successful business growth.

By Taren Grom • Jan. 24, 2022

Evofem CEO Saundra Pelletier aims to level the playing field between men's and women's health

Evofem CEO and PharmaVoice100, Saundra Pelletier, discusses funding challenges for women's health.

By Alexandra Pecci • Jan. 23, 2022

What the opera can teach pharma about patient communication

With his opera knowledge, Inozyme’s Director of Investor Relations Stefan Riley uses his unique perspective to tell the company's   compelling story.

By Kim Ribbink • Jan. 23, 2022

Woman of the Week: Pfizer CMO Dr. Aida Habtezion

Pfizer's CMO shares her experiences transforming the company's R&D culture and improving health equity

By Taren Grom • Jan. 19, 2022

Vaxxinity looks to pioneer the next revolution in pharma

With a one-of-a-kind platform and novel candidates for major indications, Vaxxinity wants to disrupt the industry’s paradigm of success. 

By Meagan Parrish • Jan. 14, 2022

Pharma execs reveal the industry's most pressing issues

Several market factors — including COVID — are driving changes and trends in the industry.

By Taren Grom • Jan. 14, 2022

Pharma M&A stagnated in 2021 — here's what could help it rebound

There are plenty of reasons pharma could get its M&A groove back in 2022.

By Meagan Parrish • Jan. 13, 2022

Welcome to the new PharmaVoice

A similar mission, a new format, and our plans for PharmaVoice's next chapter.

By Davide Savenije • Jan. 13, 2022

5 trends shaping clinical trial regulations in 2022

As agencies respond to innovations in pharma, notable shifts in 2022 are on the way.

By Meagan Parrish • Jan. 11, 2022

Biote CEO breaks down barriers in women's health

Women’s health is coming into sharper focus in 2022, but getting funding is still difficult.

By Robin Robinson • Jan. 11, 2022

Ovid's CEO shares his vision for rare disease developments

Jeremy Levin, chairman and CEO of Ovid Therapeutics discusses the keys to success in rare disease innovation.

By Kim Ribbink • Jan. 10, 2022

How the executive VP of HR at Incyte is tackling pharma's hiring woes

In an industry undergoing rapid growth, the increasing job opening rates and limited talent pool are taking on a new level of importance.

By Meagan Parrish • Jan. 10, 2022

Rare disease innovation in 2022

More companies are targeting gene therapies for rare disease treatments.

By Kim Ribbink • Jan. 5, 2022

PharmaVoice 100 Who's on the List – By Category

Who’s on the List — 2021 Indexed by Category Commanders & Chiefs Dr. Sam Agresta Foghorn Therapeutics Alisha Alaimo Biogen Shideh Bina Insigniam Dr. Norbert Bischofberger Kronos Bio Dr. James Kyle Bryan IQVIA Biotech Victor Bultó Novartis Pharmaceuticals Dr. Tony ...

By PharmaVoice Team • Aug. 1, 2021